Immunoablative therapy followed by autologous hematopoietic stem cell transplantation as the first-line disease-modifying therapy in patients with multiple sclerosis

Article Clinical Neurology

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II

Jutta Gaertner et al.

Summary: The study showed that ofatumumab is more effective and safer than teriflunomide in recently diagnosed, treatment-naive patients with relapsing multiple sclerosis. Compared with teriflunomide, ofatumumab significantly reduced the annualized relapse rate, delayed confirmed disability worsening, and delayed progression independent of relapse activity.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Review Medicine, General & Internal

Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis

F. Piehl

Summary: Treatment of multiple sclerosis is evolving with the approval of novel and increasingly effective disease-modulatory therapies. In clinical development, inhibitors of Bruton's tyrosine kinase represent a new emerging drug class in MS. Accumulating evidence suggests the importance of early high effective therapy while maintaining acceptable tolerability.

JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Article Clinical Neurology

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis

J. Das et al.

Summary: The study demonstrates that AHSCT as a first-line DMT for patients with 'aggressive' MS is safe and effective in inducing rapid and sustained remission. Patients showed improvement in EDSS score and no further relapses were reported during follow-up.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Clinical Neurology

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis

Vivien Haeussler et al.

Summary: This study compared the outcomes of patients with highly active multiple sclerosis treated with either autologous hematopoietic stem cell transplantation (aHSCT) or alemtuzumab. The results showed that more patients in the aHSCT group maintained no evidence of disease activity and experienced improvement in EDSS compared to those in the alemtuzumab group.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study

Christina Zhukovsky et al.

Summary: In this study, treatment with AHSCT was associated with a higher likelihood of maintaining 'no evidence of disease activity', while adverse events were more frequent in the first 100 days. On the other hand, treatment with ALZ had fewer adverse events initially but became more common later on.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)

Add to Collection

Article Clinical Neurology